AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT02803892
Drug: Placebo 2
RxNorm normalized name: Ethinyl Estradiol/Norethindrone Acetate;Placebo 20 MCG-1 MG; NA Oral Tablet, Disintegrating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 2 will be administered BID starting from day 0. After 8 weeks of treatment patients will discontinue placebo 2
Trial: NCT01808482
Drug: Part A: 100 mg/mL GSK2618960
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/mL GSK2618960 solution for IV Infusion up to 1 hr except for the 1st dose (IV bolus) and 2nd dose (IV infusion over 5 min) of Part A
Trial: NCT01808482
Drug: Part A: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01808482
Drug: Part B: Dose of GSK2618960 decided from Part A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A
Trial: NCT01808482
Drug: Part B: matching placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo
Trial: NCT01808482
Drug: Part C: Dose of GSK2618960 decided from Part A and B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg/mL GSK2618960 solution for IV Infusion in repeat dose decided from Part A and B
Trial: NCT01206764
Drug: RAD001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03343548
Drug: normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2cc of normal saline will be administered epidurally
Trial: NCT02294266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single oral dose placebo
Trial: NCT00833326
Drug: ARRY-334543, EGFR/ErbB2 inhibitor; oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: multiple dose, escalating
Trial: NCT00833326
Drug: Prophylactic growth factors; subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: standard of care
Trial: NCT00005649
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00256451
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo pills
Trial: NCT04600349
Drug: Treatment as Usual
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The participants randomised in this group will continue taking the classical treatment prescribed for Hashimoto (Levothyroxine)
Trial: NCT01703468
Drug: Oxcarbazepine
RxNorm normalized name: Oxcarbazepine
DrugBank: Oxcarbazepine (DB00776)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00747214
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00747214
Drug: DMARD Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DMARD therapy can include methotrexate or other DMARD therapy
Trial: NCT00771368
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 % Gaseous Nitric Oxide, delivered for 30 minutes daily for 3 consecutive days
Trial: NCT02718937
Drug: Matching placebo capsules
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04451083
Drug: FOY-305
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple-dose of FOY-305 will be administered orally at 4 times/day.
Trial: NCT01498289
Drug: FOLFOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV. Fluorouracil, oxaliplatin, \& leucovorin calcium.
Trial: NCT01498289
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m\^2, IV bolus on Day 1 of each 14 day cycle; 2400 mg/m\^2 IV over 46-48 hours on Days 1-2 of each 14 day cycle.
Trial: NCT01498289
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 400 mg/m\^2, IV over 2 hours on Day 1 of every 14 day cycle.
Trial: NCT00004261
Drug: EF5
RxNorm normalized name: Hb 76(EF5), Met-thr
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00833755
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To compare pain threshold, pain tolerance, and wind up, as measured by QST, before and after a single dose of ketamine infusion under two clinical conditions: chronic pain patients on opioid therapy and chronic pain patients without opioid therapy.
Trial: NCT00125502
Drug: MF59 adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oil-in-water emulsion
Trial: NCT00125502
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Normal saline solution
Trial: NCT02182557
Drug: WAL 801 CL Dry Syrup
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02182557
Drug: WAL 801 CL Dry Syrup placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00221741
Drug: Fresh Frozen Plasma (blood product)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00244439
Drug: MALG
RxNorm normalized name: Amalgam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 minute application
Trial: NCT00244439
Drug: Ovide (malathion) lotion 0.05%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8-12 hour application
Trial: NCT04163874
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo delivered in a basal-bolus manner with a fixed ratio with insulin.
Trial: NCT00981617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo taken once daily for 12 weeks
Trial: NCT01387269
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo tablets identical in appearance to active tablets; oral administration QD for 12 weeks, at least 1 hour before meal
Trial: NCT03054402
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose of placebo
Trial: NCT03172676
Drug: Clarithromycin 15 mg/kg/day in 2 divided doses for 14 days.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: chronic immune thrombocytopenic purpura patients who will be diagnosed positive for helicobacter pylori infection will receive Clarithromycin for 14 days.
Trial: NCT01222299
Drug: placebo comparator nasal product
RxNorm normalized name: placebo Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: sterile nasal product
Trial: NCT03794778
Drug: pegylated liposomal doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PLD 30 mg/m2, i.v.,d1; once every 21days
Trial: NCT00562965
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: intravenous cyclophosphamide at a dose of 750 mg/m2 on day 1
Trial: NCT00847093
Drug: LMX4 Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One inch every six hours
Trial: NCT01972711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral dose placebo
Trial: NCT00031551
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01354925
Drug: Standard of care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of care during Ramadan according to physicians decision
Trial: NCT00004233
Drug: fluorouracil
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00004233
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00492011
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramelteon placebo-matching tablets, orally, once nightly for 4 nights.
Trial: NCT00416273
Drug: No intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants in the observation group will be observed and will not receive any consolidation therapy.
Trial: NCT00846365
Drug: Azilsartan medoxomil and chlorthalidone
RxNorm normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil 20 mg and chlorthalidone 12.5 mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 40 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.
Trial: NCT00846365
Drug: Azilsartan medoxomil and chlorthalidone
RxNorm normalized name: Azilsartan Medoxomil and Chlorthalidone Tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azilsartan medoxomil 40 mg and chlorthalidone 12.5, mg, tablets, orally, and olmesartan medoxomil-hydrochlorothiazide placebo tablets once daily for 8 weeks.~If participant does not achieve target blood pressure at Week 4, then the dosage will be increased to azilsartan medoxomil 80 mg and chlorthalidone 25 mg, tablets, orally, once daily for the remaining 4 weeks.
Trial: NCT02754258
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 days on oral placebo administered 2 times daily before lunch and supper
Trial: NCT01806415
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of placebo or lactose 150 mg
Trial: NCT00252993
Drug: DDP225
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03131141
Drug: BC-3781
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lefamulin (BC-3781) is a potent, semi-synthetic antibacterial belonging to a novel class for systemic human use known as the pleuromutilins
Trial: NCT01124617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo will be administered as oral tablet at dose ranging from 25 mg to 250 mg twice daily for 12 weeks.
Trial: NCT02857868
Drug: ABL001
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03133676
Drug: KA34
RxNorm normalized name: Ketamine
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 µg - 400 µg intra-articular injection (single or multiple doses)
Trial: NCT03133676
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 µg - 400 µg intra-articular injection (single or multiple doses)
Trial: NCT00392106
Drug: sotolol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-arrhythmic Drug prescribed for treatment of Atrial Fibrillation
Trial: NCT01813422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT01653743
Drug: MSJ-0011
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects who underwent ovarian stimulation with follitropin alfa according to a low-dose step-up protocol for maximum of 28 days will receive a single dose of 250 microgram (mcg) MSJ-0011 (choriogonadotropin alfa \[recombinant human Chorionic Gonadotropin, r-hCG\]) subcutaneously (SC) within 32 hours after the last dose of follitropin alfa administration unless dominant follicle reached a mean diameter of greater than or equal to (\>=) 18 millimeter (mm); not more than 3 follicles each with a mean diameter of \>=16 mm and serum Estradiol (E2) level within an acceptable range for the number of follicle present, and not more than 2,000 picogram per milliliter (pg/mL).
Trial: NCT03704298
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered according to package insert
Trial: NCT00873353
Drug: capecitabine + erlotinib
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 6 cycles (3 weeks each one) of :~* capecitabine 1000mg/m2, bid, oral. Days: 1-14 every three weeks~* erlotinib (Tarceva®) 150mg/day, oral. Days: every days
Trial: NCT01403610
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo administered preoperatively, followed by postoperative combination therapy bevacizumab at 10mg/kg every 2 weeks and TH-302 at 240 - 480 mg/m2 every 2 weeks (4 week cycle) until disease progression. Subjects will be randomized (2:1) to receive pre-operative dose of TH-302.
Trial: NCT00547261
Drug: SSR97225
FDA approved: no
EMA approved: no
PMDA approved: no
Description: every 3 weeks
Trial: NCT03610633
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Saline solution.
Trial: NCT01782339
Drug: Combination Chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of: Day 1 Actinomycin D 1mg/m2, Paclitaxel 80mg/m2, Methotrexate Day 4 Oxaliplatin 100mg/m2 Pegfilgrastim 6mg Day 8\* Paclitaxel 80mg/m2 Day 15 Paclitaxel 80mg/m2~\*Day 8 will be omitted for the first three patients treated in this study and will be given at the end of treatment in a fifth cycle where Paclitaxel 80mg/m2 will be administered on Days 1, 8, 15 and 22. Before adding the extra Paclitaxel 80mg/m2 dose on day 8 the safety data for these patients will be reviewed by a DMC.~NB This 5th cycle for patients 1-3 has been included to ensure that the four 'missed doses of paclitaxel are not omitted from the patients treatment regimen. Cycles 1-4 are 21 days cycles; Cycle 5 (for the first three patients only) is a 28 day cycle.
Trial: NCT03424239
Drug: Zoledronic Acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 5mg zoledronic acid
Trial: NCT00903201
Drug: SB656933
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg
Trial: NCT00903201
Drug: SB656933
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50mg
Trial: NCT00903201
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03082885
Drug: Thymosin-α1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.6 mg s.c injection once per day for 7 days, then 1.6 mg s.c injection twice a week for 11 weeks.
Trial: NCT01870609
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sugar pill manufactured to mimic defactinib tablet
Trial: NCT01477567
Drug: LY3009385
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01477567
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03042546
Drug: Calcium Sulfate
RxNorm normalized name: Calcium Sulfate
DrugBank: Calcium sulfate (DB15533)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium Sulfate with abx will be used in the defect
Trial: NCT00185159
Drug: Placebo Tablets
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets
Trial: NCT03681197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In placebo group,placebo will be strted twice daily at booking time and continued with induction by clomiphene citrate, it will be stopped once pregnancy is confirmed.
Trial: NCT01155375
Drug: Oral Iron
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active Comparator: Oral iron
Trial: NCT00357942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo mouthwash
Trial: NCT00357942
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo solution for injection every 3 hour for 24 hours
Trial: NCT03425838
Drug: CDK 4/6 inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
Trial: NCT03425838
Drug: Non-Steroidal Aromatase Inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adding CDK 4/6 inhibitor (pabociclib, ribociclib or abemaciclib depending on availability and physician's preference) to either first line treatment (with non-steroidal aromatase inhibitors, either letrozole or anastrozole) or second line treatment (with fulvestrant) in advanced HR+/HER2-negative breast cancer
Trial: NCT00887250
Drug: Comparator: Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to Losartan
Trial: NCT01536353
Drug: AGSAV301
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet, q.d.
Trial: NCT01536353
Drug: Exforge 10/160
RxNorm normalized name: Exforge 10/160 Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet, q.d.
Trial: NCT01737268
Drug: FK949E
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral tablet
Trial: NCT03376945
Drug: control cohort
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Structolipid Glucose, lipid emulsion, amino acids, fat-and water-soluble vitamins as well as electrolytes were compounded in an All-In-One manner. 20% Structolipid and 10% Omegaven (ω-3 FA mainly; Fresenius-Kabi, Germany) were applied to the trial group, but only Structolipid (ω-6 FA mainly) to the control group for 5 consecutive days postoperatively.
Trial: NCT01306097
Drug: Zinc Supplement
RxNorm normalized name: Zinc supplement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg daily for under 1 years old children and 20mg daily for above 1 years old children
Trial: NCT00160862
Drug: SLV317
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02941185
Drug: Devit-3 Oral Drop
RxNorm normalized name: DEVILS CLAW
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00093808
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05547659
Drug: Acetaminophen 1 G Oral Tablet
RxNorm normalized name: Acetaminophen 1 g oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetaminophen 1 G Oral Tablet preoperative in multi-modal group
Trial: NCT00427336
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 300 mg/m\^2 by vein daily over 2 hours
Trial: NCT05547659
Drug: Celecoxib 400Mg Oral Capsule
RxNorm normalized name: Celecoxib 400mg Oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Celecoxib 400Mg Oral Capsule preoperative in multi-modal group
Trial: NCT01190670
Drug: ASP015K
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT04364516
Drug: Anticoagulation
RxNorm normalized name: monitoring agent for oral anticoagulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Study of prognostic impact according to oral anticoagulation therapy (Vitamin K Antagonists or Direct Oral Anticoagulants)
Trial: NCT00176735
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00336544
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clarithromycin 250 mg twice per day (BID) for 7 days, administered orally
Trial: NCT00843349
Drug: LC Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for Lanthanum Carbonate
Trial: NCT01570764
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prednisone 15 mg/d + monthly pulse cyclophosphamide 700 mg/m ² diminished to 600 mg/m ² in patients over 65 years or having a creatinine clearance lower than 30 ml/min for 12 months.
Trial: NCT01570764
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone 15 mg/d + monthly pulse of placebo of cyclophosphamide. The posology and the methods of administration of the placebo of cyclophosphamide (NaCl) will be the same as those used for cyclophosphamide
Trial: NCT01922999
Drug: Melatonin
RxNorm normalized name: Melatonin
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: patients will receive placebo, 1mg melatonin or 3mg melatonin
Trial: NCT00544219
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 750 mg/m2 i.v. per cycle
Trial: NCT00544219
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 i.v. per cycle
Trial: NCT01719133
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: saline solution
Trial: NCT02926937
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: tablet;~Route of administration: oral
Trial: NCT02215538
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo medication appears identical to the active medication OROS methylphenidate
Trial: NCT02425709
Drug: Diclofenac
RxNorm normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Women will receive oral diclofenac 50 mg 1 hour before the procedure
Trial: NCT02425709
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women will receive an oral placebo 1 hour before the procedure
Trial: NCT01719133
Drug: AllerT1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: synthetic peptide T1
Trial: NCT01719133
Drug: AllerT2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: synthetic peptide T2
Trial: NCT01719133
Drug: AllerT3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: synthetic peptide T3
Trial: NCT01719133
Drug: AllerT4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: synthetic peptide T4
Trial: NCT01559090
Drug: MEDI-546
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage I: 100 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks
Trial: NCT01559090
Drug: MEDI-546
RxNorm normalized name: Medi-Lyte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stage I: 300 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks